文献速递免疫规划传染病防控与疫情报告

四价脑膜炎球菌ACWY-破伤风类毒素结合疫苗加强剂后5岁儿童长期抗体持久性

Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
PubMed 文献 · Vaccine · 2020-04-11

本研究评估5岁儿童接种四价脑膜炎球菌ACWY-破伤风类毒素结合疫苗(MenACWY-TT)或C群脑膜炎球菌-CRM197结合疫苗(MenC-CRM)加强剂后长达6年的抗体持久性和安全性。结果显示,MenACWY-TT组rSBA滴度≥1:8的比例在加强后2年为96.7%–100%,6年为71.6%–94.0%;hSBA滴度≥1:4的比例在2年为70.0%–100%,6年为58.5%–98.5%。未报告疫苗相关严重不良事件或效力缺乏事件。

要点

  • MenACWY-TT加强后6年rSBA抗体持久性仍较高。
  • hSBA抗体持久性随时间的下降较rSBA明显。
  • 两种疫苗加强后均未发现安全性问题。

核心结论

  • MenACWY-TT或MenC-CRM加强后6年(初免后10年)rSBA和hSBA抗体均显示持久性,提示该接种程序可能提供长期保护。

研究设计与样本

  • 研究纳入184名受试者(MenACWY-TT组159人,MenC-CRM组25人),初免于12–23月龄,4年后加强,评估加强后2–6年抗体持久性和安全性。

主要发现

  • MenACWY-TT组加强后2年rSBA滴度≥1:8的比例为96.7%–100%,6年为71.6%–94.0%。
  • MenACWY-TT组加强后2年hSBA滴度≥1:4的比例为70.0%–100%,6年为58.5%–98.5%。
  • rSBA GMTs从第2年至第4年下降,此后基本稳定。
  • 未报告效力缺乏、严重不良事件或疫苗相关不良事件。

临床怎么用

  • 该长期抗体持久性数据支持在儿童中按初免后4年加强接种MenACWY-TT或MenC-CRM以预防侵袭性脑膜炎球菌病。

局限性

  • MenC-CRM组样本量较小(25人),可能影响该组结果的精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To provide continuing protection, available meningococcal vaccines must provide long-term persistence of circulating functional antibodies against prevalent serogroups causing invasive meningococcal disease (IMD). This study assessed antibody persistence and safety of the quadrivalent meningococcal vaccine conjugated to tetanus toxoid (MenACWY-TT) and the meningococcal serogroup C vaccine conjugated to Corynebacterium diphtheriae CRM197 protein (MenC-CRM) for up to 6 years after booster dosing in children. METHODS: In the primary vaccination study, children were vaccinated at age 12 to 23 months. In the first extension study, children who completed the primary study received a booster dose 4 years later with the same primary vaccine. The current study assessed antibody persistence at 2 to 6 years postbooster against each of the 4 meningococcal serogroups using serum bactericidal assays using rabbit (rSBA) or human (hSBA) complement with antibody titer thresholds of ≥1:8 or ≥1:4, respectively, and geometric mean titers (GMTs). Safety evaluations during this period included serious adverse events (SAEs) related to vaccination and any event related to lack of vaccine efficacy. RESULTS: A total of 184 subjects were enrolled (MenACWY-TT = 159; MenC-CRM = 25). For MenACWY-TT, the percentages of subjects with rSBA titers ≥1:8 ranged from 96.7% to 100% across serogroups at 2 years postbooster and 71.6% to 94.0% at 6 years postbooster; rSBA GMTs decreased from Year 2 to 4 and generally remained stable thereafter. The percentages of subjects in the MenACWY-TT group with hSBA titers ≥1:4 were 70.0% to 100% across serogroups at 2 years postbooster and 58.5% to 98.5% at 6 years postbooster. No lack of efficacy, SAEs, or vaccine-related adverse events were reported. CONCLUSIONS: The persistence of rSBA and hSBA antibodies was shown up to 6 years postbooster (10 years postprimary vaccination) with either MenACWY-TT or MenC-CRM, suggesting that this schedule may provide long-term protection against IMD. Clinicaltrials.gov: NCT01900899.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vesikari T, Forsten A, Laudat F, et al. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children. Vaccine. 2020. PMID: 32284274. doi:10.1016/j.vaccine.2020.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。